drugset / Trial / NCT05207085

Efficacy of Valbenazine for the Treatment of Trichotillomania in Adults

NCT05207085

Phase 2 Recruiting 20 enrolled Yale University Neurocrine Biosciences · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This trial aims to evaluate the efficacy, safety and tolerability of valbenazine, titrated to the subject's optimal dose of 40mg or 80mg, administered once daily, for 12 weeks, for the treatment of trichotillomania (TTM) in a double blind placebo controlled design study. After week 12, subjects will begin a 12-week, open-label portion of the study. During the open-label portion of the study, all subjects will receive the study drug at their optimal dose. The primary endpoint of these studies will be the change from baseline of placebo vs. active scores utilizing the Massachusetts General Hospital Hairpulling Scale (MGH-HPS) at the end of Week 12.

Timeline

Start
2024-02-02
Primary completion
2027-02-15
Completion
2027-02-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Valbenazine Small molecule 40 mg Oral
Subject Valbenazine Small molecule 80 mg Oral

Indications